Last night I attended an event organised by the Psychadelic Society, highlighting the potential to use psilocybin for the treatment of depression.

The event coincides with the launch of a compaign to reschedule psilocybin, which would make research less difficult and allow doctors to prescribe it.

Here is Dr. Rosalind Watts talking about her research:

I lost my dad to depression when I was young, and I expect most of us know someone who has a friend or family member who has experienced depression. Suicide is the biggest killer of men under 50, and we have some challenges maintaining good mental health for our children. Current treatment involving SSRI’s may be cheap at 71p per month, but its effectiveness varies.

If psilocybin has the potential to add to the range of treatments, it makes sense to reschedule it for further investigation.

Here’s the panel discussion from the first part of the evening:

Present are:

Stephen Reid, founder of the Psychadelic Society

Dr. James Rucker, Head of Psychedelic Research at King’s College London

Dr. Rosalind Watts, Clinical Psychologist at Imperial College London and co-host of the Psychedelic Integration Discussion Group

David Badcock, acting CEO of drugscience.

One of the speakers mentioned The Loop in the context of legalisation to promote safety; The Loop provide drug testing at festivals and clubs.

You can find out more about psilocybin on the Psychadelic Society’s campaign page.